| Active substance | sotatercept |
| Holder | Merck Sharp & Dohme LLC, A subsidiary of Merck & Co. Inc |
| Status | Running |
| Indication | Adult patients with Pulmonary Arterial Hypertension (PAH) with WHO Functional Class (FC) II/III”. |
| Public documents | Approbation |
| Approbation amendment | |
| Information for the patient | |
| Informed consent | |
| Last update | 03/12/2024 |